agomab
The Senior Project Toxicologist leads non-clinical safety within cross-functional drug development teams, shaping safety strategy from candidate selection through clinical development. This role establishes company positions for global health-authority interactions and informs external-asset and business development decisions. The position requires integrating toxicology, safety pharmacology, and translational evidence to assess human relevance and clinical mitigation.
Agomab Therapeutics (Nasdaq: AGMB) is a clinical-stage biopharmaceutical company focused on fibro-inflammation, developing growth factor-modulating therapies to treat fibrotic diseases. The company's pipeline includes Ontunisertib (AGMB-129), AGMB-447, and AGMB-101, with active clinical programs targeting conditions such as fibrostenosing Crohn's disease and idiopathic pulmonary fibrosis. Headquartered in Antwerp, Belgium, Agomab translates deep expertise in growth factor biology into disease-modifying treatments aimed at halting or reversing fibrosis and restoring organ function.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for agomab.
Senior Toxicologist, Non-Clinical Pharmacology Scientist
Sobi
Senior Toxicologist, Non-Clinical Pharmacology Scientist
Sobi
Director, Toxicology Translational Science
Tarsus Pharmaceuticals
Translational Lead
Tonix Pharmaceuticals
Director, Toxicology Translational Science
Tarsus Pharmaceuticals
Director, Toxicology Translational Science
Tarsus Pharmaceuticals